Make a gift by December 2nd, 2025 to double your impact.
NETRF is pleased to announce awards for world-class research to explore the potential of immunotherapy in NETs. This rapidly expanding class of therapies has proven
Michael German, MD has been named a Petersen Investigator for his work to explore the use of an FDA approved inhibitor of Mek1/2 in preclinical
The Neuroendocrine Tumor Research Foundation is excited to be working with Pattern.org to empower patients to direct their excess cancer tissue samples to research projects.
The first NETRF/ERF Nuclear Medicine Pilot Research Grant has been awarded to Thomas Hope, MD, of the University of California at San Francisco (UCSF). NETRF
The NETRF Board of Directors is pleased to announce that Josh Mailman has joined the Board. Josh is an internationally-recognized advocate for Neuroendocrine tumor patients
Dr. Guillermina Lozano, Ph.D. of MD Anderson Cancer Center has worked tirelessly to understand how pancreatic neuroendocrine tumors develop so that we might use that
Dr. Christopher Heaphy of Johns Hopkins University has been selected as the first Basic Translational Science Investigator, through a collaboration between NETRF and The North
The NET Research Foundation is delighted to welcome Dr. Chrissie Thirlwell, Senior Lecturer and Consultant in Medical Oncology at the Royal Free Hospital NET Unit
Funding to find cure for rare cancer affecting over 170,000 Americans The Neuroendocrine Tumor (NET) Research Foundation today announced that it has received a major
CAR T (Chimeric Antigen Receptor T-cell) therapy, an immunotherapy that harnesses the body’s own T cells to kill cancer cells, showed success in treating blood